Immunogenetic restriction on elicitation of antibodies
US11104722B2 · kind B2 · utility
0Cited by
22References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 28, 2019 |
| Grant date | Aug 31, 2021 |
| Priority date | — |
| Expiry date | Jan 28, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.